logo-loader
viewWeight Watchers International

Broker roundup, including Weight Watchers, Valeant Pharma and Rogers Communications

The analysts at Barclays took a shine to Weight Watchers (NYSE:WTW) today upgrading the shares to 'equalweight' from 'underweight'.

shutterstock_204165478.jpg
A look at some of today\\\'s broker views...

The analysts at Barclays took a shine to Weight Watchers (NYSE:WTW) today upgrading the shares to 'equalweight' from 'underweight'.

The target price was also lifted to US$14 a share from US$5.

Ealier this week, it emerged one of the most popular US talk show hosts had taken a stake in the Weight Watchers parent firm.
 
Oprah Winfrey, the presenter of the eponymously named show, purchased a 10% stake in the global slimming group Weight Watchers International for US$43mln and will take a seat on the board.

Also in broker world on Wednesday, drugs giant GlaxoSmithKline  was pushed up to 'neutral' from 'underperform' by Credit Suisse.

Rogers Communications (TSE:RCI) gained over a percentage point to US$49.68 on the day as Macquarie raised its rating to 'outperfom' from 'neutral'.

On the flipside, CIBC is less upbeat on Valeant Pharmaceuticals International (NYSE: VRX) and downgrades it to 'sector perform' from ' sector outperform'.

Shares lost over 27% to US$106.47.

Quick facts: Weight Watchers International

Price: 37.755 USD

NASDAQ:WW
Market: NASDAQ
Market Cap: $2.54 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn reveals more promising results from its clinical trials in breast cancer

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the late-stage biotechnology company has revealed additional “promising results” from its clinical trials evaluating its lead drug leronlimab for the treatment of metastatic triple-negative breast cancer and metastatic breast...

44 minutes ago

2 min read